Consequently, pharmacological reagents could be developed to reduce IRF5 or increase IRF4 expression in microglia after stroke, so that the pro-inflammatory response can be prevented and the anti-inflammatory response trigger earlier to clear the ischemic detriment and boost the tissue repair. This evidence concerns the gene IRF4 and Stroke.